# InxMed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inxmed

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.inxmed.com
- Total disclosed funding: $118M
- Latest round: Series C (Aug 22, 2025)
- Investors on record: 13

## About

Established in 2017 and based in Shanghai, China, InxMed is a biotechnology company that focuses on the R&D of oncology drug resistance and tumor metastasis fields. The company established translational medicine and clinical teams in Shanghai, Beijing, and Nanjing in China, and hubs in the United States, Canada, and Australia. Moreover, the company has established cooperation with multinational pharmaceutical companies including Roche, Boehringer Ingelheim, and MSD. The company developed a new drug for ovarian cancer, IN10018, which was approved for Investigational New Drug (IND) application in April 2020, receives US FDA Fast Track Designation for ovarian cancer in August 2021, and receives the NMPA approval for a clinical trial of solid tumor in December 2021. In August 2025, InxMed raised Series C funding led by new investor Fosun Health Capital and participants by new investors Proxima Ventures, Kunlun Capital, Chengxiang Capital, returning investor Ennovation Ventures.
The company's main business is the research, development, and production of anti-cancer drugs. The company's self-developed adhesive spot kinase (FAK) inhibitor IN10018 overcomes the drug resistance of KRAS G12C inhibitors and synergizes with KRAS G12C inhibitors in treating cancer, and can treat solid tumors, and ovarian cancers. The company also developed new drugs IN 30705 targeting cancer-associated fibroblast, and IN20130 targeting epigenetic regulators. InxMed generates revenue via researching, development, and production of anti-cancer drugs.

## Funding rounds

- Series C, Aug 22, 2025, $34M — Proxima Ventures, Ennovation Ventures, Kunlun, Fosun Health Capital, Chengxiang Capital
- Series B, May 9, 2022, $15M — Hyfinity Investments
- Series B, Mar 4, 2022, $50M — China Merchants Capital, Shanxi Growth Enterprise Leading Fund, HosenCare Brothers, Ennovation Ventures, AIHC Capital
- Series A, Sep 4, 2020, $19M — Grand Yangtze Capital, China Growth Capital, Ennovation Ventures, InnoMed Capital

## Investors

- Grand Yangtze Capital (https://capitalatlas.ai/funds/grand-yangtze-capital) — Series A
- China Growth Capital (https://capitalatlas.ai/funds/china-growth-capital) — Series A
- Ennovation Ventures (https://capitalatlas.ai/funds/ennovation-ventures) — Series A, Series B, Series C
- InnoMed Capital (https://capitalatlas.ai/funds/innomed-capital) — Series A
- China Merchants Capital (https://capitalatlas.ai/funds/china-merchants-capital) — Series B
- Shanxi Growth Enterprise Leading Fund (https://capitalatlas.ai/funds/shanxi-growth-enterprise-leading-fund) — Series B
- HosenCare Brothers (https://capitalatlas.ai/funds/hosencare-brothers) — Series B
- AIHC Capital — Series B
- Hyfinity Investments (https://capitalatlas.ai/funds/hyfinity-investments) — Series B
- Proxima Ventures (https://capitalatlas.ai/funds/proxima-ventures) — Series C
- Kunlun (https://capitalatlas.ai/funds/kunlun) — Series C
- Fosun Health Capital (https://capitalatlas.ai/funds/fosun-health-capital) — Series C
- Chengxiang Capital — Series C